Cyclodextrin-based polymers for therapeutics delivery
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-047/48
A61K-031/337
C08G-069/44
C08B-031/00
B82Y-005/00
C08B-037/16
C08B-030/00
A61K-031/7048
G06F-019/00
C08F-220/28
C08F-220/58
C08F-222/22
C08G-081/02
G06Q-050/22
출원번호
US-0061868
(2013-10-24)
등록번호
US-9550860
(2017-01-24)
발명자
/ 주소
Cheng, Jianjun
Davis, Mark E.
Khin, Kay T.
출원인 / 주소
CERULEAN PHARMA INC.
대리인 / 주소
Lando & Anastasi, LLP
인용정보
피인용 횟수 :
0인용 특허 :
129
초록▼
The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and red
The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.
대표청구항▼
1. A method of making a water soluble linear polymer taxane conjugate comprising: providing a water soluble linear polymer comprising cyclodextrin moieties and comonomers which do not contain cyclodextrin moieties (comonomers), wherein the cyclodextrin moieties and comonomers alternate in the water
1. A method of making a water soluble linear polymer taxane conjugate comprising: providing a water soluble linear polymer comprising cyclodextrin moieties and comonomers which do not contain cyclodextrin moieties (comonomers), wherein the cyclodextrin moieties and comonomers alternate in the water soluble linear polymer and wherein the water soluble linear polymer comprises at least four cyclodextrin moieties and at least four comonomers; andcovalently attaching taxane moieties to the water soluble linear polymer, thereby making a water soluble linear polymer taxane conjugate, wherein each of the taxane moieties are attached to the water soluble linear polymer via a linker. 2. The method of claim 1, wherein the linker comprises glycine or a derivative thereof. 3. The method of claim 1, wherein the water soluble linear polymer is made by a process comprising: providing cyclodextrin moiety precursors,providing comonomer precursors, andcopolymerizing said cyclodextrin moiety precursors and comonomer precursors to thereby make the water soluble linear polymer comprising cyclodextrin moieties and comonomers. 4. The method of claim 1, comprising providing cyclodextrin moiety precursors modified to bear one reactive site at each of exactly two positions, and reacting the cyclodextrin moiety precursors with comonomer precursors having exactly two reactive moieties capable of forming a covalent bond with the reactive sites under polymerization conditions that promote reaction of the reactive sites with the reactive moieties to form covalent bonds between the comonomers and the cyclodextrin moieties, whereby a water soluble linear polymer comprising alternating units of a cyclodextrin moiety and a comonomer is produced. 5. The method of claim 1, wherein the taxane moieties make up at least 5% by weight of the water soluble linear polymer conjugate. 6. The method of claim 1, wherein the taxane moieties make up at least 10% by weight of the water soluble linear polymer conjugate. 7. The method of claim 1, wherein the taxane moieties make up at least 15% by weight of the water soluble linear polymer conjugate. 8. The method of claim 1, wherein each of the comonomers comprises polyethylene glycol and the cyclodextrin moieties comprise beta-cyclodextrin. 9. The method of claim 3, wherein each comonomer precursor is a compound containing at least two functional groups through which reaction and thus linkage of the cyclodextrin moieties is achieved. 10. The method of claim 9, wherein the at least two functional groups, which may be the same or different, terminal or internal, of each comonomer precursor comprise an amino acid, imidazole, hydroxyl, thio, acyl halide, —HC═CH—, —C≡C— group, or derivative thereof. 11. The method of claim 9, wherein the at least two functional groups are the same and are located at termini of each comonomer precursor. 12. The method of claim 1, wherein each of the comonomers contains one or more pendant groups with at least one functional group through which reaction and thus linkage of the taxane moieties is achieved. 13. The method of claim 12, wherein the functional groups, which may be the same or different, terminal or internal, of the one or more pendant groups comprise an amino acid, imidazole, hydroxyl, thiol, acyl halide, ethylene, ethyne group, or derivative thereof. 14. The method of claim 12, wherein the one or more pendant groups are a substituted or unsubstituted branched, cyclic or straight chain C1-C10 alkyl, or arylalkyl optionally containing one or more heteroatoms within the chains or rings. 15. The method of claim 1, wherein the cyclodextrin moieties comprise an alpha, beta, or gamma cyclodextrin moiety. 16. The method of claim 1, wherein the cyclodextrin moieties comprise a beta cyclodextrin moiety. 17. The method of claim 1, wherein administration of the water soluble linear polymer taxane conjugate to a patient results in release of the taxane moieties over a period of at least 6 hours. 18. The method of claim 1, wherein administration of the water soluble linear polymer taxane conjugate to a patient results in release of the taxane moieties over a period of 6 hours to a month. 19. The method of claim 1, wherein, upon administration of the water soluble linear polymer taxane conjugate to a patient the rate of taxane moieties release is dependent primarily upon the rate of hydrolysis as opposed to enzymatic cleavage. 20. The method of claim 1, wherein the water soluble linear polymer taxane conjugate has a molecular weight of 10,000-500,000 amu. 21. The method of claim 1, wherein the water soluble linear polymer taxane conjugate has a molecular weight of 30,000-520,000 amu. 22. The method of claim 1, wherein the water soluble linear polymer taxane conjugate has a molecular weight of 70,000-150,000 amu. 23. The method of claim 1, wherein the cyclodextrin moieties make up at least about 2% of the polymer by weight. 24. The method of claim 1, wherein the cyclodextrin moieties make up at least about 5% of the polymer by weight. 25. The method of claim 1, wherein the cyclodextrin moieties make up at least about 10% of the polymer by weight. 26. The method of claim 1, wherein the cyclodextrin moieties make up at least about 20% of the polymer by weight. 27. The method of claim 1, wherein the cyclodextrin moieties make up at least about 30% of the polymer by weight. 28. The method of claim 1, wherein each of the comonomers comprises a group selected from the following: an alkylene chain,polysuccinic anhydride,poly-L-glutamic acid,poly(ethyleneimine),an oligosaccharide, oran amino acid chain. 29. The method of claim 1, wherein each of the comonomers comprises a polyethylene glycol. 30. The method of claim 1, wherein each of the comonomers comprises a polyethylene glycol of molecular weight 0.2 kDa to 5 kDa. 31. The method of claim 1, wherein each of the comonomers comprises a group selected from the following: polyglycolic acid or polylactic acid chain. 32. The method of claim 1, wherein each of the comonomers comprises a hydrocarbylene group wherein one or more methylene groups is optionally replaced by a group Y (provided that none of the Y groups are adjacent to each other), wherein each Y, independently for each occurrence, is selected from, substituted or unsubstituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, or —O—, C(═X) (wherein X is NR1, O or S), —OC(O)—, —C(═O)O—, —NR1—, —NR1CO—, —C(O)NR1—, —S(O)n— (wherein n is 0, 1, or 2), —OC(O)—NR1—, —NR1—C(O)—NR113 , —NR1—C(NR1)—NR1—, and —B(OR1)—; and R1, independently for each occurrence, represents H or a lower alkyl. 33. The method of claim 1, wherein the linker comprises glycine, each of the comonomers comprises a polyethylene glycol, and the cyclodextrin moieties comprise beta-cyclodextrin. 34. A method of making a water soluble linear polymer taxane conjugate having the following formula: the method comprising: providing a polymer of the formula below: and covalently attaching a plurality of D moieties to the polymer to provide: wherein represents a cyclodextrin, each L is independently a linker, each D is a taxane moiety or absent, the group has a Mw of 0.2 kDa to 5 kDa, and n is at least 4. 35. A method of making a water soluble linear polymer taxane conjugate having the following formula: the method comprising: providing cyclodextrin moiety precursors of the following formula: providing comonomer precursors of the following formula: copolymerizing the cyclodextrin moiety precursors and the comonomer precursors to provide a water soluble linear polymer; andcovalently attaching a plurality of L-D moieties to the water soluble linear polymer, to provide the water soluble linear polymer taxane conjugate,wherein represents a cyclodextrin, each L-D is a linker-taxane moiety or absent, the group has a Mw of 0.2 kDa to 5 kDa, and n is at least 4. 36. The method of claim 34, wherein represents beta-cyclodextrin. 37. The method of claim 35, wherein represents beta-cyclodextrin. 38. The method of claim 34, wherein the water soluble linear polymer taxane conjugate has a molecular weight of 30,000-520,000 amu. 39. The method of claim 35, wherein the water soluble linear polymer taxane conjugate has a molecular weight of 30,000-520,000 amu. 40. The method of claim 34, wherein the cyclodextrin moieties make up at least about 5% of the polymer by weight. 41. The method of claim 35, wherein the cyclodextrin moieties make up at least about 5% of the polymer by weight.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (129)
Ekwuribe Nnochiri ; Ramaswamy Muthukumar ; Rajagopalan Jayanthi Sethuraman, Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same.
Winkler, James L.; Fodor, Stephen P. A.; Buchko, Christopher J.; Ross, Debra A.; Aldwin, Lois; Modlin, Douglas N., Combinatorial strategies for polymer synthesis.
Low Philip Stewart (West Lafayette IN) Horn Mark Alan (Piscataway NJ) Heinstein Peter Frederick (West Lafayette IN), Composition and method for tumor imaging.
Curiel David T. (Chapel Hill NC) Birnstiel Max L. (Vienna ATX) Cotten Matthew (Vienna ATX) Wagner Ernst (Langenzersdorf ATX) Zatloukal Kurt (Vienna ATX) Plank Christian (Vienna ATX) Oberhauser Berndt, Composition for introducing nucleic acid complexes into higher eucaryotic cells.
Grinstaff Mark W. (Pasadena CA) Soon-Shiong Patrick (Los Angeles CA) Wong Michael (Champaign IL) Sandford Paul A. (Los Angeles CA) Suslick Kenneth S. (Champaign IL) Desai Neil P. (Los Angeles CA), Composition useful for in vivo delivery of biologics and methods employing same.
Wolff, Jon A.; Hagstrom, James E.; Monahan, Sean D.; Budker, Vladimir; Rozema, David B.; Slattum, Paul M., Compositions and methods for drug delivery using amphiphile binding molecules.
Zemel Haya (Des Plaines IL) Koch Mark B. (Des Plaines IL) Rohrbach Ronald P. (Des Plaines IL), Crosslinked cyclodextrins supported on porous refractory inorganic oxides.
Weltrowski, Marek; Morcellet, Michel; Martel, Bernard, Cyclodextrin polymers and/or cyclodextrin derivatives with complexing properties and ion-exchange properties and method for the production thereof.
Soon-Shiong Patrick (Los Angeles CA) Desai Neil P. (Los Angeles CA) Sandford Paul A. (Los Angeles CA) Heintz Roswitha A. (Los Angeles CA) Sojomihardjo Soebianto (Pasadena CA), Gel compositions prepared from crosslinkable polysaccharides, polycations and/or lipids and uses therefor.
Pirrung Michael C. (Durham NC) Read J. Leighton (Palo Alto CA) Fodor Stephen P. A. (Palo Alto CA) Stryer Lubert (Stanford CA), Large scale photolithographic solid phase synthesis of an array of polymers.
Pirrung Michael C. (Durham NC) Read J. Leighton (Palo Alto CA) Fodor Stephen P. A. (Palo Alto CA) Stryer Lubert (Stanford CA), Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof.
Vgtle Friedrich (St. Augustin DEX) Dix Johannes P. (Bonn-Beuel DEX) Jaworek Dieter (Weilheim DEX), Ligands assayed by host molecules including cyclophanes, crown ethers, crypstands and podands.
Phillips Christopher P. (Brandamore PA) Snow Robert A. (West Chester PA), Lyophilized polyethylene oxide modified protein and polypeptide complexes with cyclodextrin.
Wahlig Helmut (Darmstadt DEX) Dingeldain Elvira (Dreieich DEX) Braun Dietrich (Darmstadt-Arheilgen DEX), Medicinally useful, shaped mass of collagen resorbable in the body.
Wahlig Helmut (Darmstadt DEX) Dingeldein Elvira (Dreieich DEX) Braun Dietrich (Darmstadt DEX), Medicinally useful, shaped mass of collagen resorbable in the body.
Rhett L. Affleck ; Doug Hobbs ; Ilya Feygin ; Gregory L. Kirk ; James A. Connelly ; Ning Zhao ; James P. Mueller ; Peter Kieselbach, Method and apparatus for controlled photoelution.
Wu George Y. (Bloomfield CT) Wu Catherine H. (Bloomfield CT), Method for the introduction of genes into mammalian cells by a soluble molecular complex comprising a receptor ligand an.
Toda Fumio (Ehime JPX) Tanaka Koichi (Matsuyama JPX) Nakata Tetsuya (Ibaraki JPX), Method of optically resolving a racemate or a diastereomeric mixture of glycidyl compound.
Davis,Mark E.; Gonzalez,Hector; Hwang,Suzie (Sue Jean), Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network.
Desai Neil P. (Los Angeles CA) Soon-Shiong Patrick (Los Angeles CA) Sandford Paul A. (Los Angeles CA) Grinstaff Mark W. (Pasadena CA) Suslick Kenneth S. (Champaign IL), Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful th.
Garvey, David S.; Letts, L. Gordon; Lin, Chia-En; Richardson, Stewart K.; Wang, Tiansheng, Nitrosated and nitrosylated taxanes, compositions and methods of use.
Tsuchiyama Yukio (Yokohama JPX) Sato Michikatsu (Fujisawa JPX) Yagi Yoshiaki (Fujisawa JPX) Ishikura Tomoyuki (Chigasaki JPX), Partially methylated cyclodextrins and process for producing the same.
Casey Donald J. (Ridgefield CT) Huffman Kenneth R. (Stamford CT), Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same.
Hyon Suong-Hyu (Uji JPX) Ikada Yoshita (Uji JPX), Polylactic acid type microspheres containing physiologically active substance and process for preparing the same.
DeLuca Patrick P. (Lexington KY) Kanke Motoko (Fukuyama JPX) Sato Toyomi (Tokyo CA JPX) Schroeder Hans G. (Encinitas CA), Porous microspheres for drug delivery and methods for making same.
Desai, Neil P.; Tao, Chunlin; Yang, Andrew; Louie, Leslie; Yao, Zhiwen; Soon-Shiong, Patrick; Magdassi, Shlomo, Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof.
Colin Michel (Thoiry FRX) Guenard Daniel (Montrouge FRX) Gueritte-Voegelein Francoise (Paris FRX) Potier Pierre (Paris FRX), Taxol derivatives, their preparation and pharmaceutical compositions containing them.
Bachmann Frank (Freiburg DEX) Lohmann Dieter (Munchenstein CHX) Chabrecek Peter (Basel CHX), Unsaturated carbohydrate derivatives polymers thereof and their use.
Fodor Stephen P. A. (Palo Alto CA) Stryer Lubert (Stanford CA) Pirrung Michael C. (Durham NC) Read J. Leighton (Palo Alto CA), Very large scale immobilized polymer synthesis.
Szejtli Jzsef (Budapest HUX) Fenyvesi va (Budapest HUX) Zsadon Bla (Budapest HUX) Szilasi Mria (Budapest HUX) Dcsei Lajos (Budapest HUX), Water soluble cyclodextrin polymers substituted by ionic groups and process for the preparation thereof.
Nussstein Peter (Munich DEX) Staudinger Guenther (Munich DEX) Kreuzer Franz-Heinrich (Martinsried DEX) Schmitt-Sody Wolfgang (Wolfratshausen DEX), Water-insoluble cyclodextrin polymers and processes for their preparation.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.